3608-67-1

Usage

Uses

Used in Pharmaceutical Industry:
1-methyl-4-piperidyl diphenylglycolate is used as an antispasmodic agent for its ability to alleviate muscle spasms and spasticity. It is incorporated into pharmaceutical formulations to provide relief from conditions characterized by involuntary muscle contractions.
1-methyl-4-piperidyl diphenylglycolate is used as a muscle relaxant for its efficacy in reducing muscle contractions, making it a valuable component in treatments aimed at improving motor function and managing discomfort associated with muscle stiffness.
Used in Neurological Applications:
In the field of neurology, 1-methyl-4-piperidyl diphenylglycolate is being investigated for its potential use in the treatment of Parkinson's disease. Its therapeutic properties are being studied to understand its impact on motor symptoms and the overall management of the disease.

InChI:InChI=1/C20H23NO3/c1-21-14-12-18(13-15-21)24-19(22)20(23,16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18,23H,12-15H2,1H3

Upstream product

• 106-52-5 N-methyl-4-hydroxypiperidine 
• 52182-15-7 ethyl benzilate 
• 80154-05-8 1-methylpiperidin-4-ol monohydrochloride 
• 2902-98-9 2-chloro-2,2-diphenylacetyl chloride 
• 74-83-9 methyl bromide 
• 64749-86-6 3-benziloyloxy-1-(2,2-dimethyl-1,3-dioxolan-4ylmethyl)piperidine 
• 60569-19-9 propiverine 
• 54556-98-8 propiverine hydrochloride 
• 76-89-1 methyl benzilate 
• 76-93-7 Benzilic acid 

Downstream Products

• 5634-41-3 4-benziloyloxy-1,1-dimethyl-piperidinium; bromide 
• 38528-48-2 hydroxy-DAMP 
• 25811-48-7 2,2-diphenyl-2-hydroxyacetic acid (piperidine-4-yl) ester 
• 111051-49-1 1-methyl-4-piperidyl benzilate N-oxide 
• 76-93-7 Benzilic acid 
• 55190-56-2 3-hydroxy-3-phenylbenzo-2(3H)-furanone 
• 117-99-7 2-Hydroxybenzophenone 
• 107411-17-6 4-Hydroxy-benzilsaeure 
• 1137-42-4 4-Hydroxybenzophenone 
• 107412-86-2 2-hydroxybenzilic acid 
• 118108-69-3 Benzilsaeure(1-methylpiperid-4-yl)ester-N-oxide 
• 118108-70-6 Benzilsaeure(1-methylpiperid-4-yl)ester-N-oxide 
• 106-52-5 N-methyl-4-hydroxypiperidine 
• 91614-25-4 trans 4-benziloyloxy-1-trideuteriomethyl-1-methylpiperidinium bromide 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS

The present invention relates to novel compounds of formula (1): The present invention also discloses compounds of formula (1) along with other pharmaceutical acceptable excipients and use of the compounds as anti-tubercular agents.

QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS

Compounds of formula (I), in salt or zwitterionic form, wherein J, L, M, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Synthesis, antimuscarinic activity and quantitative structure-activity relationship (QSAR) of tropinyl and piperidinyl esters

A series of tropinyl and piperidinyl esters was synthesized and evaluated for inhibitory activities on the endothelial muscarinic receptors of rat (M3) and rabbit (M2) aorta. Some of the esters (cyclohexylphenylglycolates and cyclohexylphenylpropionates) were found to be better antimuscarinic compounds than standard M2 and M3 inhibitors such as AFDX116 and 4-diphenylacetoxy-N-methylpiperidine (DAMP), with pKEC50 values in the range of 8-9. A few esters were found to be more selective M3 than M2 inhibitors, but these tended to have low activities. The hydrophobic, electronic and steric characteristics of these esters were correlated with antimuscarinic activity by using appropriate parameters representing hydrophobicity (HPLC capacity factor, log k(w), size (molecular volume) and electronic character (Taft's polar substituent constant δ and 13C chemical shift difference Δδ). Finally, 92% of the M2-inhibitory activities of the esters could be accounted for by the size and electronic character σ* of the side chain. In contrast, the M3-inhibitory activities of these esters were mainly attributed to the electronic nature (σ*, Δδ) of the side chain, with good activity being associated with electron-withdrawing groups. Visualization of the comparative molecular field analysis (CoMFA) steric and electrostatic fields provided further confirmation of the structure-activity relationship (SAR) derived from traditional quantitative structure-activity relationship (QSAR) approaches.

Biomimetic investigations of propiverinhydrochloride and 1-methyl-4-piperidyl benzilate

The reaction of propiverinhydrochloride (1) and 1-methyl-4-piperidyl benzilate (2) with the biomimetic system manganese(III)-5,10,15,20-tetrakis(pentafluorophenyl)-β-tetrasulfonat oporphyrin chloride (MnTPFPS4PCl)/imidazole/hydrogen peroxide in aqueous solution at pH 7-8 affords unchanged 1 and 2 and numerous metabolites, which are products of fission of the ester bond, of O-dealkylation, decarboxylation, N-demethylation, and oxidation of the tertiary amine function. In contrast to the nonaqueous system with the catalyst manganese(III)-5,10,15,20-tetrakis(pentafluorophenyl)porphyrin chloride (MnTPFPPCl) aromatic hydroxylation is not observed. This result shows conformity with the studies of metabolism in men.

Biomimetic oxidation of propiverinhydrochloride and 1-methyl-4-piperidyl benzilate

The reaction of propiverinhydrochloride (1) and 1-methyl-4-piperidyl benzilate (2) with the biomimetic system manganese(III)-5,10,15,20-tetrakis(pentafluorophenyl)porphyrin chloride (MnTPFPPCl)/pyridine/hydrogen peroxide affords unchanged 1 and 2 and 15 potential metabolites, which were isolated and identified. These compounds are products of cleavage of the ester bond, of O-dealkylation, aromatic oxidation, respectively of decarboxylation, demethylation, and N-oxidation. Products were identified by TLC, UV, and MS in comparison with authentic samples. Thereby we found a nearly conformity with rat metabolism.